Infliximab was used as the positive control as it inhibits the production of TNF-α and is used as anti-TNF-α therapy for IBD treatment clinically.[29,30] PH46 (2) and compound 8, its unsubstituted benzyl analogue, displayed potent IL-6 inhibition with levels of inhibition of 92.07% (0.132 ± 0.038 pg/μg ml) and 95.49% (0.075 ± 0.019 pg/μg ml), respectively, over CTRL 1. Here, IL6 is linked to inflammatory bowel disease.